Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.46 |
| ▸ | PPARG | P37231 | 7/20 | 0.46 |
| ▸ | PPARD | Q03181 | 7/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6238997 | 1.00 | TSHR (0.50) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL3677555 | 1.00 | TSHR (0.50) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL28293188 | 1.00 | TSHR (0.50) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL3672035 | 1.00 | TSHR (0.50) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL28887112 | 1.00 | TSHR (0.50) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL7994628 | 1.00 | TSHR (0.50) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL7994715 | 0.98 | LMNA (0.48) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL620276 | 0.91 | LMNA (0.43) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL5705529 | 0.90 | KMT2A (0.52) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL1225161 | 0.89 | LMNA (0.42) | TSHRLMNANFKB1PMP22GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3906231-A2 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | Lupin Limited (IN) | 2021-11-10 | — | — | EP | claimed |
| WO-2020141419-A2 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | LUPIN LIMITED (IN) | 2020-07-09 | — | — | WO | claimed |
| US-20220249380-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GRANULATED BEMPEDOIC ACID | RUBICON RESEARCH PVT. LTD. (IN) | 2022-08-11 | — | — | US | disclosed |
| EP-3906231-A2 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | Lupin Limited (IN) | 2021-11-10 | — | — | EP | disclosed |
| EP-3752133-A1 | SUSTAINED RELEASE FORMULATIONS OF BEMPEDOIC ACID | Esperion Therapeutics, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020141419-A2 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | LUPIN LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
| WO-2019161307-A1 | SUSTAINED RELEASE FORMULATIONS OF BEMPEDOIC ACID | ESPERION THERAPEUTICS, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20180338922-A1 | FIXED DOSE FORMULATIONS | ESPERION THERAPEUTICS, INC. | 2018-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249380-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GRANULATED BEMPEDOIC ACID | PCSK9, HMGCR, APOB | TSHR 4800/4885LMNA 410/4885NFKB1 341/4885 |
| US-20180338922-A1 | FIXED DOSE FORMULATIONS | APOB, PCSK9, HMGCR | TSHR 4642/4885LMNA 250/4885NFKB1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.